These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 14348839)

  • 21. Identification and validation of cell surface antigens for antibody targeting in oncology.
    Carter P; Smith L; Ryan M
    Endocr Relat Cancer; 2004 Dec; 11(4):659-87. PubMed ID: 15613445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the enzyme method for antibody identification.
    Strobel E
    Clin Lab; 2004; 50(9-10):575-80. PubMed ID: 15481633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
    Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
    Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer.
    Lu H; Goodell V; Disis ML
    J Proteome Res; 2008 Apr; 7(4):1388-94. PubMed ID: 18311901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody engineering principles and applications.
    Loo L; Robinson MK; Adams GP
    Cancer J; 2008; 14(3):149-53. PubMed ID: 18536554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.
    Egloff AM; Weissfeld J; Land SR; Finn OJ
    Ann N Y Acad Sci; 2005 Dec; 1062():29-40. PubMed ID: 16461786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum antibody positivity for distinct Helicobacter pylori antigens in benign and malignant gastroduodenal disease.
    Schumann C; Triantafilou K; Rasche FM; Möricke A; Vogt K; Triantafilou M; Hahn P; Schneider EM; Lepper PM
    Int J Med Microbiol; 2006 Aug; 296(4-5):223-8. PubMed ID: 16600680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study of the humoral immune response of breast cancer patients to a panel of human tumor antigens identified by phage display.
    Pavoni E; Pucci A; Vaccaro P; Monteriù G; Ceratti Ade P; Lugini A; Virdis RA; Cortesi E; De Gaetano A; Panunzi S; Felici F; Minenkova O
    Cancer Detect Prev; 2006; 30(3):248-56. PubMed ID: 16876336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
    Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
    J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible applications of antibodies or their genes in cancer therapy.
    Kuroki M; Huang J; Shibaguchi H; Tanaka T; Zhao J; Luo N; Hachimine K; Kinugasa T; Maekawa S; Enatsu S; Hamanaka W; Fukami T; Kuroki M
    Anticancer Res; 2006; 26(6A):4019-25. PubMed ID: 17195452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer.
    Ryschich E; Märten A; Schmidt E; Linnebacher M; Wentzensen N; Eisold S; Klar E; Büchler MW; Schmidt J
    Eur J Cancer; 2006 May; 42(7):981-7. PubMed ID: 16564167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ACTH and antibody formation].
    VAN DER SLIKKE LB; KEUNING FJ
    Ned Tijdschr Geneeskd; 1953 Oct; 97(44):2886-7. PubMed ID: 13119786
    [No Abstract]   [Full Text] [Related]  

  • 37. The mode of stroma formation in transplanted mouse carcinoma.
    VON NUMERS C
    Ann Med Exp Biol Fenn; 1953; 31(3)(Suppl):327-37. PubMed ID: 13171700
    [No Abstract]   [Full Text] [Related]  

  • 38. Mobility and site of production of homograft resistance factor.
    PREHN RT; MAIN JM
    J Natl Cancer Inst; 1954 Jun; 14(6):1277-80. PubMed ID: 13233862
    [No Abstract]   [Full Text] [Related]  

  • 39. Conditioning of the host.
    TOOLAN HW
    J Natl Cancer Inst; 1953 Dec; 14(3):745-67; discussion, 767. PubMed ID: 13233825
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antibody formation and cancer growth].
    SEELICH F
    Wien Klin Wochenschr; 1954 Sep; 66(35-36):635-8. PubMed ID: 14348839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.